FDA Declines Merck ‘Guided Missile’ Lung Cancer Drug

The U.S. Food and Drug Administration declined to approve Merck and Japan-based Daiichi Sankyo’s lung cancer treatment, which belongs to a lucrative class of cancer therapies that work like “guided missiles. “The FDA cited findings from an inspection of a third-party…[#item_full_content]